QCG
SPRO icon

Quadrant Capital Group’s Spero Therapeutics SPRO Stock Holding History

Quadrant Capital Group’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-106
Closed -$1K – 2720
2022
Q1 		$1K Buy
+106
New +$1.09K ﹤0.01% 2391

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Quadrant Capital Group's SPRO Position: Q2 2022 in Review

Quadrant Capital Group sold out of Spero Therapeutics (SPRO) in Q2 2022, closing a stake of 106 shares — an estimated $1K sold.

Quadrant Capital Group first reported a position in SPRO in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 79 funds tracked by Wall St. Rank hold SPRO as of Q2 2022.

  • Quadrant Capital Group reported no remaining Spero Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Quadrant Capital Group sold 106 Spero Therapeutics shares in Q2 2022, an estimated $1K.
  • Quadrant Capital Group first reported a position in Spero Therapeutics in Q1 2022 and held it in 1 quarter.
  • Quadrant Capital Group's Spero Therapeutics position peaked at $1K in Q1 2022.
  • 79 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2022.

Based on Quadrant Capital Group's 13F filing for Q2 2022, filed 9 Aug 2022.